Rockefeller Neuroscience Institute

Embr Labs announces study results revealing improvement in sleep in among men and women

Retrieved on: 
Wednesday, February 7, 2024
National Sleep Foundation, West Virginia University, Sleep, Temperature, Wave, Somnolence, Foremost, Rockefeller Neuroscience Institute, Quality of life, Doctor of Philosophy, Woman, Pharmaceutical industry

BOSTON, Feb. 7, 2024 /PRNewswire/ -- Embr Labs , Inc, makers of Embr Wave®, the leading temperature wearable, today announced pivotal sleep study results showing that subjects who wore the Embr Wave demonstrated a significant improvement in several measures of sleep quality including perceived sleepiness, sleep quality, reduced nocturnal resting heart rate, and increased sleep efficiency.

Key Points: 
  • BOSTON, Feb. 7, 2024 /PRNewswire/ -- Embr Labs , Inc, makers of Embr Wave®, the leading temperature wearable, today announced pivotal sleep study results showing that subjects who wore the Embr Wave demonstrated a significant improvement in several measures of sleep quality including perceived sleepiness, sleep quality, reduced nocturnal resting heart rate, and increased sleep efficiency.
  • A first of its kind study, Embr labs collaborated with leading human performance researchers at the.
  • West Virginia University Rockefeller Neuroscience Institute to examine the impact of the Embr Wave thermal wearable on sleep quality in men and women.
  • The study follows Embr Labs' recognition by the National Sleep Foundation as a SleepTech Award winner and the Embr Labs brand being named to the Foremost 50 list of breakthrough consumer brands.

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

Retrieved on: 
Monday, October 2, 2023
Alvogen, Priority review, Patent, Partnership, Rockefeller Neuroscience Institute, Schnitzer, Nociception, File, Spinal cord, Clinical trial, Licensure, Coronavirus Scientific Advisory Board, United States patent law, NMDA, Research, CNS, Feinberg School of Medicine, Dark Enlightenment, Data collection, Pain, Thalamus, Investigational New Drug, Patient, Risk, Ketamine, DCS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Northwestern University, Food, Pharmaceutical industry, Poultry farming, Defense, Anesthesia, Chronic pain, IND, Surgery

RADNOR, Pa., Oct. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.

Key Points: 
  • RADNOR, Pa., Oct. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.
  • "More than one in five adults in the United States suffers from chronic pain and patients lack options that do not carry the risk of addiction and opioid side effects.
  • Chronic pain is estimated to be a $72 billion industry today with the potential to grow to a $120 billion industry by 2033.
  • Dr. Apkarian is the inventor of the patent and a global expert in pain research and has important experience studying DCS in chronic pain.

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

Retrieved on: 
Wednesday, August 30, 2023
Alvogen, Priority review, Patent, Partnership, Rockefeller Neuroscience Institute, Nociception, Schnitzer, Spinal cord, Drug discovery, Clinical trial, Licensure, DSM-IV codes, United States patent law, Coronavirus Scientific Advisory Board, Medication, NMDA, Research, Brain, Tylenol, CNS, Feinberg School of Medicine, Dark Enlightenment, Data collection, Pain, Thalamus, Nonsteroidal anti-inflammatory drug, Ketamine, DCS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Northwestern University, Food, Pharmaceutical industry, Dietary supplement, Vaccine, Poultry farming, Defense, Anesthesia, File, Chronic pain, Surgery

The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.

Key Points: 
  • The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.
  • Chronic pain is estimated to be a $72 billion industry today with the potential to grow to a $120 billion industry by 2033.
  • Dr. Apkarian is the inventor of the patent and a global expert in pain research and has important experience studying DCS in chronic pain.
  • In experimental models and clinical studies, NMDA antagonists have demonstrated attenuation of pain and shown potential to reduce opioid craving.

NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain

Retrieved on: 
Monday, August 7, 2023
SAB, Patent, Rockefeller Neuroscience Institute, Nociception, Spinal cord, Perception, United States Air Force Scientific Advisory Board, NMDA, Research, Brain, CNS, Feinberg School of Medicine, Pain, US, Crave, Thalamus, Neuropathic pain, Ketamine, DCS, License, Northwestern University, Dark Enlightenment, Dietary supplement, Pharmaceutical industry, Vaccine, Anesthesia, Chronic pain, Surgery, Medicine, Northwestern

The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids.

Key Points: 
  • The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids.
  • "We delighted welcome Dr. Apkarian to the NRx SAB," said Jonathan Javitt, Chief Scientist and Founder of NRx Pharmaceuticals.
  • "Adding a scientist of Vania's caliber will be invaluable to advancing our clinical program in Chronic Pain."
  • In June 2023, the Company announced a focus on chronic pain as the next focus on NRX-101's development.

Precision Neuroscience Begins First-in-Human Study of its Neural Interface Technology

Retrieved on: 
Tuesday, June 6, 2023
Epilepsy, Hair, Partnership, University, Speech, Neoplasm, Brain, Neurosurgery, Research, Rockefeller Neuroscience Institute, RNI, Language, Precision, Sale, Patient, Universal Medicine, Map, University of Pennsylvania Health System, WVU, Mount Sinai Health System, Massachusetts General Hospital, FDA, Cortex, Medical imaging, Industrial design

NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation today announced that the first-in-human procedures in a pilot clinical study of its neural implant system have been successfully completed.

Key Points: 
  • NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation today announced that the first-in-human procedures in a pilot clinical study of its neural implant system have been successfully completed.
  • The Precision Neuroscience system, called the Layer 7 Cortical Interface, contains 1,024 tiny electrodes spanning an area of one square centimeter, embedded in a flexible film that conforms to the brain surface.
  • “Precision technology has the potential to redefine the standard of care in clinical neuroscience,” said Dr. Benjamin Rapoport, a neurosurgeon and the Chief Science Officer at Precision Neuroscience.
  • Since the first procedure, completed in mid-April at the RNI, two additional patients have undergone similar operations using the Precision system.

Burjeel Holdings and US-based Northwell Health To Launch Neuroscience Institute in UAE

Retrieved on: 
Friday, June 9, 2023
Research, Neurology, Hospitals, Clinical Trials, Health Technology, Health Insurance, Health, Pharmaceutical, Science, Epilepsy, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, BMC, Donald, Partnership, Rockefeller Neuroscience Institute, DSM-IV codes, Multimedia, Department of Neurology, Xuanwu hospital, Multiple sclerosis, Northwell Health, Organization, MD, Patient, Knowledge, MENA, SVP, Nursing, Management, Pharmaceutical industry

The collaboration between Burjeel Holdings and Northwell Health will enable the transfer of knowledge and expertise between the two organizations to deliver the best possible patient care.

Key Points: 
  • The collaboration between Burjeel Holdings and Northwell Health will enable the transfer of knowledge and expertise between the two organizations to deliver the best possible patient care.
  • View the full release here: https://www.businesswire.com/news/home/20230609005314/en/
    Northwell Health and Burjeel Holdings signed a Memorandum of Understanding to open the Dr. Najjar Neuroscience Institute in the UAE.
  • From left are John Sunil, CEO of Burjeel Holdings; Souhel Najjar, MD, senior vice president and executive director of the neurology service line of Northwell Health; and Michael Dowling, president and CEO of Northwell Health.
  • The ceremony was attended by Dr. Shamsheer Vayalil, founder and chairman of Burjeel Holdings; Mr. John Sunil, CEO, Burjeel Holdings; Dr. Mohan Chellappa, non-executive director, Burjeel Holdings; Michael Dowling, president and CEO, Northwell Health; Dr. Souhel Najjar, SVP and executive director of the Neurology Service Line, Northwell Health; Dinelia Ortiz, vice president, Neurology Service Line, Northwell Health; Serena Najjar, senior project manager, Neurology Global Patient Services, Northwell Health; Kevin Beiner, SVP and regional executive director western region, Northwell Health.

A Pair of Brain Regions Prompts Females to Kill or Care For Their Young

Retrieved on: 
Wednesday, June 7, 2023
Leon Levy Foundation, Male, Infanticide, Human, Rockefeller Neuroscience Institute, Nature, NYU Langone Health, NYU, MPOA, New York University Grossman School of Medicine, Woman, Aggression, Brain, Emotion, Cell, Doctor of Philosophy, National Institutes of Health, Bangladesh Technical Education Board, Mother, Publishing, Animal, Child, Psychiatry, Mouse, Death, Behavior, Female, Physiology, Nursing, Medical imaging, Neuroscience

NEW YORK, June 7, 2023 /PRNewswire/ -- A middle-brain region tied to the control of emotions likely prompts females to kill their young, a new study in mice shows.

Key Points: 
  • NEW YORK, June 7, 2023 /PRNewswire/ -- A middle-brain region tied to the control of emotions likely prompts females to kill their young, a new study in mice shows.
  • This behavior may have evolved to preserve scarce food supplies for their own future offspring, according to experts.
  • However, most studies have focused on infanticide by adult males, and the brain mechanism behind this behavior in females has until now remained poorly understood.
  • The mice rarely attacked other adults, the authors say, suggesting that the structure specifically controls aggression toward young animals.

Gene Mutation May Explain Brain Cell Plaque Buildup in Alzheimer's Disease

Retrieved on: 
Wednesday, November 30, 2022
Doctor of Philosophy, Cure Alzheimer's Fund, National Institutes of Health, Cell, NYU Langone Health, Mutation, Gene, Hasel, Glaucoma, New York University Grossman School of Medicine, DNA, Bacteria, Brain, Enzyme, Alzheimer's Research UK, INPP5D, Physiology, Alzheimer's Association, Inflammation, Rockefeller Neuroscience Institute, Microglia, Parkinson's disease, NYU, Plaque, Icahn School of Medicine at Mount Sinai, Neurodegeneration, Multiple sclerosis, Journal, Mouse, Ophthalmology, Virus, Monroe Dunaway Anderson, Huntington's disease, Research, Human, Mount Sinai, BA, Vaccine, Pharmaceutical industry, Medical imaging, Antibiotics, Neuroscience, Dementia, MD, Shelly Liddelow, Alzheimer's disease, Medicine

The buildup of such clumps, also called plaque, sets off an immune response that can kill brain cells and may lead to the dementia associated with Alzheimer's disease.

Key Points: 
  • The buildup of such clumps, also called plaque, sets off an immune response that can kill brain cells and may lead to the dementia associated with Alzheimer's disease.
  • The new findings may offer a potential new target for therapies that directly affect the gene mutation, according to the study authors.
  • Notably, this cluster is known to produce molecules that trigger inflammation in Parkinson's disease, Huntington's disease, and various forms of dementia.
  • They compared these findings to previous research in humans with Alzheimer's disease, observing the same genetic changes in the gene cluster linked to plaque.

Saluda Medical the First to Present 24-Month Holistic Response to Spinal Cord Stimulation

Retrieved on: 
Tuesday, July 19, 2022
Northwestern University, Department, JAMA Neurology, Quality of life, Record, Chronic pain, Physiology, University of Florida College of Medicine-Jacksonville, Feinberg School of Medicine, Multimedia, MD, Doctor of Philosophy, Institute, CEO, Low back pain, PAIN, Technology, Rockefeller Neuroscience Institute, Landmark, Method, PMA, Ion, Society, University, ASPN, Patient, Safety, Sleep, View, INS, Interface (computing), Webbed toes, Randomized controlled trial, International Neuromodulation Society, Evoke, SCS, Florida College, Publication, Neurology, Hyperreflexia, Research design, RCT, Pharmaceutical industry, Birth control, Neurosurgery, Neuroscience, Pain

ARTARMON, Australia, July 19, 2022 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by breakthrough proprietary neural sensing technology, announced Steven M. Falowski, MD, presented late-breaking 24-month data from the Landmark EVOKE study at the 2022 American Society of Pain and Neuroscience (ASPN) fourth annual meeting. The evidence presented at ASPN was the first time a company has published data from a pivotal randomized controlled trial (RCT) capturing pain relief as well as quality of life, functional status, sleep, and mood improvements. Together with pain relief, these outcome measures constitute "holistic outcomes."

Key Points: 
  • Historically, patients prescribed a spinal cord stimulator have been evaluated primarily on pain reduction or responder rate (>50% pain relief).
  • The consortium's recommendation is to assess spinal cord stimulation trial outcomes on a more holistic manner that is more reflective of the chronic pain experience."
  • Saluda Medical's Evoke System is the first and only smart spinal cord stimulator that can sense and measure the spinal cord's response to stimulation.
  • Saluda Medical and Evoke are registered trademarks owned by Saluda Medical Pty Ltd.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/saluda-medical-the-first-to-pre...

ŌURA Names Tom Hale as New Chief Executive Officer

Retrieved on: 
Monday, April 25, 2022
General Health, Health, Fitness & Nutrition, Consumer Electronics, Technology, MSD, CEO, Board, University of California, San Diego, University of California, Institute for Prediction Technology, Sleep, Oura, IPO, Meditation, Culture, Berkeley, Software, Risk, Research, Life, Heart rate, Hale, Adobe, Â, DTRA, MSD Capital, Growth, Enterprise, Mental health, Temasek, Linden Lab, Technology, Pregnancy, Temperature, Peter Chernin, Wrist, Period, B2B, Rockefeller Neuroscience Institute, University, Reproductive health, Health, Ring, Software as a service, Knowledge, Cybook Gen3, Pharmaceutical industry, Momentive, Macromedia, Expedia

URA , the company behind the smart ring that delivers personalized health data, insights, and daily guidance to consumers, today announced Tom Hale as the new Chief Executive Officer and board member.

Key Points: 
  • URA , the company behind the smart ring that delivers personalized health data, insights, and daily guidance to consumers, today announced Tom Hale as the new Chief Executive Officer and board member.
  • As CEO of URA, Hale is uniquely positioned to lead the team in bringing URAs vision of health as a daily practice to consumers all over the world.
  • URA answers an urgent need: more than ever, people are focused on physical and mental health, looking to build positive habits and improve their well-being, said Tom Hale, Chief Executive Officer of URA.
  • Tom brings decades of technology leadership across both consumer and B2B businesses to URA, said Eurie Kim, Chairperson of the Board for URA.